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Purpose: Simple intensity modulation of radiation therapy reduces acute toxicity compared with 2-dimensional techniques in
adjuvant breast cancer treatment, but it remains unknown whether more complex or inverse-planned intensity modulated
radiation therapy (IMRT) offers an advantage over forward-planned, 3-dimensional conformal radiation therapy (3DCRT).
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Methods and Materials: Using prospective data regarding patients receiving adjuvant whole breast radiation therapy without
nodal irradiation at 23 institutions from 2011 to 2018, we compared the incidence of acute toxicity (moderate-severe pain or
moist desquamation) in patients receiving 3DCRT versus IMRT (either inverse planned or, if forward-planned, using ≥5 segments per gantry angle). We evaluated associations between technique and toxicity using multivariable models with inverseprobability-of-treatment weighting, adjusting for treatment facility as a random effect.
Results: Of 1185 patients treated with 3DCRT and conventional fractionation, 650 (54.9%) experienced acute toxicity; of 774
treated with highly segmented forward-planned IMRT, 458 (59.2%) did; and of 580 treated with inverse-planned IMRT, 245
(42.2%) did. Of 1296 patients treated with hypofractionation and 3DCRT, 432 (33.3%) experienced acute toxicity; of 709
treated with highly segmented forward-planned IMRT, 227 (32.0%) did; and of 623 treated with inverse-planned IMRT, 164
(26.3%) did. On multivariable analysis with inverse-probability-of-treatment weighting, the odds ratio for acute toxicity after
inverse-planned IMRT versus 3DCRT was 0.64 (95% conﬁdence interval, 0.45-0.91) with conventional fractionation and 0.41
(95% conﬁdence interval, 0.26-0.65) with hypofractionation.
Conclusions: This large, prospective, multicenter comparative effectiveness study found a signiﬁcant beneﬁt from inverseplanned IMRT compared with 3DCRT in reducing acute toxicity of breast radiation therapy. Future research should identify
the dosimetric differences that mediate this association and evaluate cost-effectiveness. Ó 2021 Elsevier Inc. All rights reserved.

Intensity modulated radiation therapy (IMRT) in breast
cancer typically refers to the division of the radiation treatment beam delivered from any single angle into smaller subsegments that differ in intensity. This intensity modulation
can be simple, involving only a few crude segments that can
be planned by a human dosimetrist, or more complex (Fig.
E1). At the extreme, it can involve pixel-by-pixel variation
of small regions, such as each square centimeter of a treatment ﬁeld, requiring inverse treatment planning. Inverse
planning can also be used to deliver simpler forms of segmentation.
Randomized trials evaluating simple IMRT in the adjuvant treatment of breast cancer after lumpectomy revealed
signiﬁcant reductions in toxicity with this approach, compared with 2-dimensional treatment planning.1,2 However,
the IMRT approach evaluated in those studies was frequently forward-planned and similar to what many US centers would call 3-dimensional conformal radiation therapy
(3DCRT) rather than IMRT, which, in the United States,
has most frequently been deﬁned by insurers as treatment
involving the division of at least 1 beam into 5 or more segments and often involves inverse planning.
Because IMRT delivery fees have historically been considerably higher—at one point more than double the rate of
3DCRT in the Center for Medicare Services fee
schedules3,4—stakeholders have wondered whether more
complex IMRT is necessary to reduce toxicity or whether
the use of 3DCRT might sufﬁce. Unfortunately, given the
rapid adoption of IMRT technology,5 a randomized trial
directly comparing 3DCRT to more sophisticated forms of
IMRT has not been feasible in the United States, although a
Korean trial recently reported ﬁndings of reduced toxicity
with IMRT among patients receiving conventionally fractionated breast radiation therapy.6 Over the past decade,
practice patterns have diverged considerably among institutions,7-9 and comparison of these 2 approaches in real-world
practice in the United States remains a key topic that must
be examined to ensure appropriate direction of clinical practice.

Therefore, in 2011, with funding from Blue Cross Blue
Shield of Michigan, we initiated a multicenter collaborative
quality initiative, the Michigan Radiation Oncology Quality
Consortium (MROQC), with a primary objective of evaluating the effect of IMRT in patients with breast cancer and
lung cancer. This article reports the primary outcomes analysis of the large, prospective observational study that was
designed to allow for meaningful comparative effectiveness
analysis of 3DCRT versus more complex forms of IMRT for
the treatment of breast cancer. Findings of the primary outcomes analysis in lung cancer will be presented separately.
Our primary aims were to compare acute toxicity with each
technique after controlling for relevant patient factors.

Methods and Materials
Data collection and sample
We obtained institutional review board approval to collect
prospectively a rich array of treatment planning data and
physician assessments for all eligible patients treated at
MROQC member institutions with whole breast radiation
therapy, as part of a quality improvement initiative.10,11 Eligible patients were women being treated with adjuvant
whole breast radiation therapy for nonmetastatic, unilateral
breast cancer without having breast implants at an
MROQC-participating institution. We also obtained institutional review board approval to collect patient-reported data
from patients who consented to participate in weekly surveys while on treatment.
Our sample was derived from the 8228 patients with
breast cancer who met the analytical eligibility criteria and
received adjuvant whole breast radiation therapy at 24 institutions participating in the MROQC between November
2011 and September 2018. Analytical eligibility criteria
included having data sufﬁcient to identify fraction size,
treatment technique (number of segments per beam and
inverse versus forward planning), and submission of a
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Fig. 1. Flow of patients into the study sample. This ﬁgure shows how patients were selected for inclusion in the analytical
sample. Abbreviations: 3DCRT = 3-dimensional conformal radiation therapy; IMRT = intensity modulated radiation therapy.
composite treatment dose-volume histogram for the breast.
We required that all patients included in the analytical sample have an end-of-treatment toxicity assessment (§7 days
from date of last fraction). We further limited this sample to
similarly treated cases, deﬁned as receiving a boost, without
nodal treatment, and treated in the supine position for
breast and boost treatment. Finally, we required at least 10
analytically eligible cases from each treating institution,
resulting in the exclusion of 9 patients from 1 institution
from the analytical sample, with the smallest remaining
institutional contribution 22 cases and the largest contribution 471.
We considered 5167 cases in total: 2539 patients treated
with conventional fractionation and 2628 treated with hypofractionation (deﬁned as utilizing a dose per fraction greater
than 2.0 Gy).12 Figure 1 details the ﬂow of patients into the
analytical sample.

Measures
The primary, predeﬁned outcome measure was clinically
meaningful acute toxicity, deﬁned using the maximum value
recorded on any on-treatment weekly evaluation or the endof-treatment evaluation. Clinically meaningful acute toxicity
was deﬁned ex ante to include either moderate to severe
pain or moist desquamation. Pain was primarily patient
reported, using an approved modiﬁcation of the Brief Pain
Inventory,13,14 in 3947 cases (76.4%) and physician-reported
using the Common Terminology Criteria for Adverse
Events (CTCAE) scale in the 1220 (23.6%) cases where
patient self-report was not provided. Moist desquamation
was physician reported, using a single item assessing presence or absence of any moist desquamation.
The primary independent variable of interest was treatment technique. Treatment technique was deﬁned as

3DCRT versus 2 forms of IMRT. All patients treated with
inverse planning were grouped together and categorized as
having received inverse-planned IMRT. Those treated with
forward planning were categorized as having received highly
segmented forward-planned IMRT if there was use of ≥5 or
more segments per any unique gantry angle for the primary
breast plan; the remainder were categorized as receiving
3DCRT (see Fig. 2 for the distributions of treatment techniques by treating facility).
Covariates used for the creation of propensity scores for
adjustment in the multivariable models were age, race
(White, Black, or other), hypertension, diabetes, body mass
index (BMI), chemotherapy receipt, whether the institution
was an academic center (trains residents or fellows), separation distance (the distance separating the entry points of
typical tangential beams at the midline and midaxillary line,
which reﬂects an aspect of the patient’s body habitus that
inﬂuences the dose homogeneity of radiation treatment),
breast volume, and D50 to the treated region (the maximum
dose delivered to 50% of the target volume, which serves as
a proxy for differences in dose prescription).

Statistical analysis
We ﬁrst described the study sample separately for patients
treated with conventional fractionation and those treated
with hypofractionation, given prior work suggesting that
these 2 groups had substantially different rates of acute
toxicity.15,16 We described the incidence of acute toxicity
and evaluated the observed, unadjusted association between
technique and toxicity in this unweighted sample.
Next, we developed propensity scores to allow for analyses using the inverse probability of treatment weighting
(IPTW), whereby each patient is weighted by the inverse of
the probability of the treatment actually received (effectively
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Fig. 2. Distribution of the use of the treatment techniques by enrolling site. This ﬁgure shows the use of the 3 forms of treatment (3DCRT, highly-segmented forward-planned IMRT, and inverse-planned IMRT) in patients treated with each fractionation approach. Abbreviations: 3DCRT = 3-dimensional conformal radiation therapy; IMRT = intensity modulated radiation
therapy.

up-weighting cases that had a low probability of receiving
the treatment that was actually received). The propensity
scores were calculated from a standard multinomial regression model predicting which treatment technique was
received, using all of the covariates listed earlier. The goal of
this propensity score creation and use of IPTW was to create
weighted samples by treatment received that have balanced
external covariates, a statistical method to make observational data resemble a randomized controlled trial.17 By balancing these important covariates through weighting, an
unbiased and unconfounded comparison by treatment
received could then be made.
Next, we estimated models using the IPTW sample. Speciﬁcally, we developed generalized linear models for the
binary outcome of acute toxicity using the logit link for the
binomial distribution to determine the association with
treatment technique, estimated as odds ratios, in each fractionation subgroup separately, after adjustment for all covariates and including the institution of treatment as a
random effect (which adjusts for differences in outcome
related to clustering of patients within each treating facility).
Finally, we conducted a sensitivity analysis that further subdivided the inverse-planned cases into 2 subgroups (those
with ≥5 segments per any unique gantry angle and those
with <5 segments for all unique gantry angles).
In addition to analyses focused on the ex ante predeﬁned
primary endpoint, we also evaluated the frequency of 2
additional endpoints: grade 3 toxicity as measured by the

CTCAE and toxicity-related treatment breaks, using IPTW
for weighting of percentages and P values for comparisons
among the 3 treatment groups.

Results
Tables 1 and 2 show the characteristics of the analyzed sample by fractionation. Mean age was 58.5 years for the conventionally fractionated sample and 62.5 years for the
hypofractionated sample. Numerous measured covariates
differed among patients treated with 3DCRT, those treated
with highly segmented forward planning, and those treated
with inverse IMRT within each fractionation subset. As
expected, these imbalances were much less after application
of IPTW (Table E1).
Of the 1185 patients treated with 3DCRT and conventional fractionation, 650 (54.9%) experienced acute toxicity;
of 774 treated with highly segmented forward-planned
IMRT, 458 (59.2%) did; and of 580 treated with inverseplanned IMRT, 245 (42.2%) did. Of 1296 patients treated
with hypofractionation and 3DCRT, 432 (33.3%) experienced acute toxicity; of 709 treated with highly segmented
forward-planned IMRT, 227 (32.0%) did; and of 623 treated
with inverse-planned IMRT, 164 (26.3%) did. As noted in
the Methods and Materials section, the acute toxicity endpoint included patient reports of pain where available
(81.9% of conventionally fractionated cases treated with
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Sample characteristics, conventionally fractionated (N = 2539)

Variable/level
Age, y
Race
White
Black
Other
Hypertension
No
Yes
Diabetes
No
Yes
Smoking status
Never
Former
Current
Hormone therapy
Missing
No
Yes
Chemotherapy
Missing
No
Yes
Group stage
0
1
2
3
Separation distance (cm)
BMI category
Underweight/Normal <25
Overweight 25-<30
Obesity I 30-<35
Obesity II 35-<40
Obesity III >40
Breast total volume (cm3)
D50 Breast (Gy)
Treatment facility academic
No
Yes

Statistics
Mean (SD)

Total population
58.5 (10.47)

3DCRT (N = 1185)
58.41 (10.42)

Highly segmented forwardplanned (N = 774)
59.15 (10.35)

Inverse-planned
IMRT (N = 580)
57.85 (10.71)

N (%)
N (%)
N (%)

1938 (76.33)
465 (18.31)
136 (5.36)

992 (83.71)
144 (12.15)
49 (4.14)

495 (63.95)
244 (31.52)
35 (4.52)

451 (77.76)
77 (13.28)
52 (8.97)

N (%)
N (%)

1500 (59.08)
1039 (40.92)

749 (63.21)
436 (36.79)

416 (53.75)
358 (46.25)

335 (57.76)
245 (42.24)

N (%)
N (%)

2188 (86.18)
351 (13.82)

1030 (86.92)
155 (13.08)

653 (84.37)
121 (15.63)

505 (87.07)
75 (12.93)

N (%)
N (%)
N (%)

1476 (58.13)
758 (29.85)
305 (12.01)

707 (59.66)
354 (29.87)
124 (10.46)

430 (55.56)
235 (30.36)
109 (14.08)

339 (58.45)
169 (29.14)
72 (12.41)

N (%)
N (%)
N (%)

26 (1.02)
909 (35.80)
1604 (63.17)

19 (1.60)
408 (34.43)
758 (63.97)

3 (0.39)
288 (37.21)
483 (62.40)

4 (0.69)
213 (36.72)
363 (62.59)

N (%)
N (%)
N (%)

13 (0.51)
1632 (64.28)
894 (35.21)

11 (0.93)
794 (67.00)
380 (32.07)

2 (0.26)
476 (61.50)
296 (38.24)

362 (62.41)
218 (37.59)

N (%)
N (%)
N (%)
N (%)
Mean (SD)

579 (22.80)
1336 (52.62)
612 (24.10)
12 (0.47)
23.21 (3.92)

293 (24.73)
616 (51.98)
270 (22.78)
6 (0.51)
22.69 (3.82)

167 (21.58)
418 (54.01)
186 (24.03)
3 (0.39)
24.12 (4.04)

119 (20.52)
302 (52.07)
156 (26.90)
3 (0.52)
23.07 (3.76)

N (%)
N (%)
N (%)
N (%)
N (%)
Mean (SD)
Mean (SD)

622 (24.50)
673 (26.51)
580 (22.84)
357 (14.06)
307 (12.09)
1194.51 (832.46)
51.23 (3.55)

318 (26.84)
308 (25.99)
274 (23.12)
158 (13.33)
127 (10.72)
1113.06 (599.38)
51.45 (3.25)

146 (18.86)
193 (24.94)
174 (22.48)
134 (17.31)
127 (16.41)
1340.9 (1118.39)
51.59 (3.53)

158 (27.24)
172 (29.66)
132 (22.76)
65 (11.21)
53 (9.14)
1165.57 (768.17)
50.32 (4.00)

N (%)
N (%)

1726 (67.98)
813 (32.02)

958 (80.84)
227 (19.16)

505 (65.25)
269 (34.75)

263 (45.34)
317 (54.66)

Abbreviations: 3DCRT = 3-dimensional conformal radiation therapy; IMRT = intensity modulated radiation therapy.

3DCRT, 76.0% treated of conventionally fractionated cases
treated with highly segmented forward-planned IMRT, and
76.0% of conventionally fractionated cases treated with
inverse planned IMRT cases; 78.9% of hypofractionated
cases treated with 3DCRT, 66.6% of hypofractionated cases
treated highly segmented forward-planned IMRT, and
73.4% of hypofractionated cases treated with inverse
planned IMRT). For the other patients, acute toxicity was
entirely based on physician reports.
Table 3 shows the results of models, including a crude
unadjusted comparison and 3 multivariable models using
the IPTW sample: one with weighting alone, one adding
covariates, and a ﬁnal adding hospital site as a random

effect. As shown, in certain models in the hypofractionated
sample, there was a signiﬁcant beneﬁt from highly segmented IMRT, but the clearest difference was between
inverse-planned IMRT and 3DCRT, which was observed in
all models.
The forest plots in Figures 3 and 4 detail the ﬁnal models.
In those models, the odds ratio for acute toxicity after
inverse-planned IMRT compared with 3DCRT was 0.64
(95% conﬁdence interval, 0.45-0.91) in patients receiving
conventional fractionation and 0.41 (95% conﬁdence interval, 0.26-0.65) in patients receiving hypofractionation. On
sensitivity analysis that subdivided the inverse-planned
cases into 2 subgroups based on number of segments,
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Table 2

Sample characteristics, hypofractionated (N = 2628)

Variable/level
Age (y)
Race
White
Black
Other
Hypertension
No
Yes
Diabetes
No
Yes
Smoking status
Never
Former
Current
Hormone therapy
Missing
No
Yes
Chemotherapy
Missing
No
Yes
Group stage
0
1
2
3
Separation distance (cm)
BMI category
Underweight/normal <25
Overweight 25-<30
Obesity I 30-<35
Obesity II 35-<40
Obesity III >40
Breast total volume (cm3)
D50 Breast (Gy)
Treatment facility academic
No
Yes

Statistics
Mean (SD)

Total population
62.53 (10.03)

3DCRT (N = 1296)
62.27 (9.82)

Highly segmented
forward-planned (N = 709)
63.7 (10.04)

Inverse-planned
IMRT (N = 623)
61.72 (10.34)

N (%)
N (%)
N (%)

2094 (79.68)
395 (15.03)
139 (5.29)

1157 (89.27)
84 (6.48)
55 (4.24)

443 (62.48)
232 (32.72)
34 (4.80)

494 (79.29)
79 (12.68)
50 (8.03)

N (%)
N (%)

1729 (65.79)
899 (34.21)

904 (69.75)
392 (30.25)

424 (59.80)
285 (40.20)

401 (64.37)
222 (35.63)

N (%)
N (%)

2342 (89.12)
286 (10.88)

1180 (91.05)
116 (8.95)

600 (84.63)
109 (15.37)

562 (90.21)
61 (9.79)

N (%)
N (%)
N (%)

1502 (57.15)
829 (31.54)
297 (11.30)

770 (59.41)
396 (30.56)
130 (10.03)

391 (55.15)
225 (31.73)
93 (13.12)

341 (54.74)
208 (33.39)
74 (11.88)

N (%)
N (%)
N (%)

27 (1.03)
843 (32.08)
1758 (66.89)

14 (1.08)
442 (34.10)
840 (64.81)

4 (0.56)
188 (26.52)
517 (72.92)

9 (1.44)
213 (34.19)
401 (64.37)

N (%)
N (%)
N (%)

7 (0.27)
2206 (83.94)
415 (15.79)

5 (0.39)
1065 (82.18)
226 (17.44)

2 (0.28)
606 (85.47)
101 (14.25)

535 (85.87)
88 (14.13)

N (%)
N (%)
N (%)
N (%)
Mean (SD)

596 (22.68)
1567 (59.63)
462 (17.58)
3 (0.11)
22.54 (3.50)

260 (20.06)
821 (63.35)
213 (16.44)
2 (0.15)
21.98 (3.22)

168 (23.70)
425 (59.94)
115 (16.22)
1 (0.14)
23.26 (3.49)

22.87 (3.88)

N (%)
N (%)
N (%)
N (%)
N (%)
Mean (SD)
Mean (SD)

728 (27.70)
863 (32.84)
576 (21.92)
275 (10.46)
186 (7.08)
1038.83 (561.61)
45.18 (2.39)

398 (30.71)
457 (35.26)
264 (20.37)
106 (8.18)
71 (5.48)
944.86 (479.10)
44.76 (2.23)

140 (19.75)
214 (30.18)
180 (25.39)
111 (15.66)
64 (9.03)
1147.88 (592.33)
45.55 (2.59)

190 (30.50)
192 (30.82)
132 (21.19)
58 (9.31)
51 (8.19)
1110.2 (646.37)
45.65 (2.33)

N (%)
N (%)

1553 (59.09)
1075 (40.91)

1075 (82.95)
221 (17.05)

398 (56.14)
311 (43.86)

168 (26.97)
321 (51.52)
134 (21.51)

80 (12.84)
543 (87.16)

Abbreviations: 3DCRT = 3-dimensional conformal radiation therapy; BMI = body mass index; IMRT = intensity modulated radiation therapy;
IPTW = inverse probability of treatment weighting.

ﬁndings were consistent in both magnitude and direction
when each of these subgroups was compared with 3DCRT,
both in patients receiving conventional fractionation and
those receiving hypofractionation, suggesting that our primary approach of pooling the inverse-planned cases in a
single category for analysis was appropriate.
Extremely severe toxicity was rare in all groups. For
hypofractionated cases, CTCAE grade 3 radiation dermatitis
occurred in 0.7% of patients treated with 3DCRT, 0.2% of
those treated with highly segmented forward-planned
IMRT, and 0% of those treated with inverse-planned IMRT
(P = .026). For conventionally fractionated cases, CTCAE

grade 3 radiation dermatitis occurred in 2.4% of patients
treated with 3DCRT, 1.8% of those treated with highly segmented forward-planned IMRT, and 1.6% of those treated
with IMRT (P = .443). Similarly, treatment breaks due to
toxicity were rare in either fractionation group. For hypofractionated cases, toxicity related treatment breaks
occurred in 0.3% receiving 3DCRT, 0% of those receiving
highly segmented forward-planned IMRT, and 0.8% of
those receiving inverse-planned IMRT (P = .053). In conventionally fractionated cases, toxicity-related treatment
breaks occurred in 5.0% of patients treated with 3DCRT,
2.1% of those treated with highly segmented forward-
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Overview of models of acute toxicity by radiation therapy technique
Proportion composite acute radiation-induced toxicity

Models/population
Conventional fractionation
Unadjusted
IPTW adjusted only
IPTW adjusted + covariates
IPTW
adjusted + covariates
+ hospital (random effect)
Hypofractionation
Unadjusted
IPTW adjusted only
IPTW adjusted + covariates
IPTW
adjusted + covariates
+ hospital (random effect)

OR [95% CI]

(1) 3DCRT
(forwardplanned,
<5 segments)

(2) Highly segmented
forward-planned IMRT
(forward planned,
5+ segments)

(3) Inverseplanned IMRT

Group 2 vs 1

Group 3 vs 1

0.5485
0.5759
0.6046
0.5732

0.5917
0.5584
0.5721
0.6034

0.4224
0.4238
0.4410
0.4626

1.19 [0.99-1.43]
0.93 [0.76-1.13]
0.87 [0.71-1.08]
1.13 [0.88-1.46]

0.60 [0.49-0.74]
0.54 [0.43-0.69]
0.52 [0.40-0.66]
0.64 [0.45-0.91]

0.3333
0.3522
0.3485
0.3637

0.3202
0.2902
0.2799
0.2999

0.2632
0.2139
0.2092
0.1894

0.94 [0.77-1.15]
0.75 [0.59-0.95]
0.73 [0.57-0.93]
0.75 [0.54-1.03]

0.71 [0.58-0.88]
0.50 [0.33-0.77]
0.49 [0.33-0.74]
0.41 [0.26-0.65]

Abbreviations: 3DCRT = 3-dimensional conformal radiation therapy; CI = conﬁdence interval; IMRT = intensity modulated radiation therapy;
IPTW = inverse probability of treatment weighting; OR = odds ratio.

planned IMRT, and 3.6% of those treated with IMRT
(P = .003). Note that the percentages and P values presented
here were weighted by IPTW.

Discussion
In this large, prospective, multicenter comparative effectiveness analysis, we observed a statistically signiﬁcant overall
beneﬁt from the use of inverse-planned IMRT compared
with 3DCRT in adjuvant whole breast radiation therapy.
The observed beneﬁt was modest in magnitude, but it
reﬂected a difference in a measure of acute toxicity (moderate or severe pain or moist desquamation) that was intentionally deﬁned a priori to be clinically meaningful. As in
prior studies, toxicity was less common in patients who
received hypofractionation, but even in this group, there
was a signiﬁcant additional reduction of acute toxicity from
the use of inverse-planned IMRT. Our ﬁndings suggest that
the use of inverse planning may help to minimize the acute
toxicity of treatment. These ﬁndings must be considered in
the context of the evolving costs associated with more complex treatment planning and delivery, with important implications for clinical practice and policy.
The current study ﬁndings complement and extend the
results of other studies investigating the optimal approach
for whole breast radiation therapy. As noted earlier, prior
randomized trials compared simpler forms of forwardplanned intensity modulation to 2-dimensional treatment
planning and demonstrated clinically signiﬁcant beneﬁts, as
also demonstrated in observational studies.18 In a Canadian
trial in 358 patients, fewer who were treated with simple
IMRT experienced moist desquamation (31.2% with IMRT

vs 47.8%, P = .002). In a large British trial of 1145 patients,
those randomized to forward-planned simple IMRT were
less likely to have suboptimal overall cosmesis (odds ratio
on multivariable modeling, 0.65; P = .038) or skin telangiectasia (odds ratio, 0.57; P = .031) at 5 years. The majority of
studies have focused on using IMRT (forward or inversely
planned) to decrease the percent of breast tissue receiving
>107% dose while increasing the proportion of the target
volume receiving 95% of the prescription dose.
Several observational studies with smaller sample sizes
have compared IMRT delivery (with either forward or
inverse-planning) to 3DCRT.19,20 One such study considered patients treated in the prone position with moderate
hypofractionation, comparing dosimetric parameters and
outcomes in 57 patients who received IMRT delivery (which
was used when insurers agreed to reimburse for it) to those
in 40 patients who received 3DCRT (because their insurers
refused coverage for IMRT). In that study, the delivery was
a combination of 3-dimensional tangents (67% of the dose)
and inverse-planned intensity modulated ﬁelds (33%),
which not only affected dosimetric parameters such as maximum dose and dose homogeneity but was also associated
with a reduced frequency of grade 2 dermatitis (13% vs
2%).20
Recently, results emerged from KROG 15-03, a randomized trial of conventionally fractionated IMRT in 1.8 Gy
fractions to the whole breast with simultaneous integrated
boost versus conventionally fractionated 3DCRT with
sequential boost. Consistent with the observations in the
current study, the trial showed lower skin toxicity with
IMRT and no difference in locoregional recurrence. Speciﬁcally, the incidence of grade ≥2 dermatitis as assessed by
clinicians was signiﬁcantly lower in the IMRT arm (37.1%
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Fig. 3. Forest plot of multivariable model of acute toxicity among patients treated with conventional fractionation. This
model uses the inverse probability of treatment weighted sample of patients treated with conventional fractionation to consider
the binary outcome of acute toxicity (having moist desquamation or moderate or severe pain). It uses the logit link for the
binomial distribution to determine the association with treatment technique, estimated as odds ratios, after adjustment for all
covariates and including the institution of treatment as a random effect. Abbreviations: 3DCRT = 3-dimensional conformal
radiation therapy; BMI = body mass index; IMRT = intensity modulated radiation therapy; ITPW = inverse probability of
treatment weighting.

vs 27.8%; P = .009). Our study complements this trial by
offering evidence from a variety of practice settings in the
United States, incorporating patient-reported outcomes and
including patients treated with hypofractionation. The consistent ﬁndings of our carefully controlled observational
comparative effectiveness study, optimized for generalizability to real-world practice in the United States, and this
recent randomized trial, optimized for causal inference, are
compelling.
When IMRT was ﬁrst developed, substantial additional
costs and resources were required for its delivery. Over
time, these differences have decreased, thanks to efforts to
develop and disseminate both simple IMRT techniques21,22
and more complex but efﬁcient approaches.23 Nevertheless,

differences in fee schedules for reimbursement of radiation
therapy using different techniques have led both to concerns
about the possible overuse of IMRT in the United States,
driven by higher reimbursement, and also concerns about
how the lack of nuance in billing codes might potentially stiﬂe innovation and drive underuse of IMRT, due to a desire
to responsibly steward resources.24 Although current Medicare fee schedules no longer reimburse IMRT at dramatically higher rates than 3DCRT and bundled payments will
soon be explored at some sites, payments by some private
insurers diverge considerably even today. Ultimately, determining whether widespread use of more complex forms of
IMRT for whole breast irradiation should be recommended
will require weighing the likelihood and magnitude of
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Fig. 4. Forest plot of multivariable model of acute toxicity among patients treated with hypofractionation. This model uses
the inverse probability of treatment weighted sample of patients treated with hypofractionation to consider the binary outcome
of acute toxicity (having moist desquamation or moderate or severe pain). It uses the logit link for the binomial distribution to
determine the association with treatment technique, estimated as odds ratios, after adjustment for all covariates and including
the institution of treatment as a random effect. Abbreviations: 3DCRT = 3-dimensional conformal radiation therapy;
BMI = body mass index; IMRT = intensity modulated radiation therapy; ITPW = inverse probability of treatment weighting.

expected beneﬁt against costs, further informed by patient
preferences and societal values. Given the greater efﬁciency
with which IMRT can now be delivered, if societal costs can
be aligned more closely with actual planning and delivery
costs, use of IMRT may indeed be preferred, in light of the
recent Korean trial and the ﬁndings of the present study.
Together, these studies offer strong evidence of a modest
incremental beneﬁt of inverse-planned IMRT, even compared with high-quality 3DCRT and delivered in the setting
of moderate hypofractionation, which itself reduces the likelihood of toxicity. That said, rates of extremely severe toxicity, such as grade 3 events or those requiring treatment
breaks, are rare regardless of technique in this sample.
Current consensus guidelines emphasize the utility of
standardizing dosimetric goals in treatment planning.25

Further research is necessary to understand the dosimetric
differences between the IMRT and 3D plans in this data set
that may have led to the difference in toxicity observed in
this study. Prior work has suggested that limiting V105%
may be helpful in larger breasted patients treated with hypofractionation.26 In addition, dose to the skin27 and/or to the
superﬁcial rind of tissue closest to skin surface may be
important and can be more closely controlled with inverse
planning.28 Additional studies to deﬁne criteria for optimizing treatment planning based on the rich dosimetric information available through the MROQC collaborative are
now under way. Particularly if the societal costs of delivering
3DCRT and IMRT remain meaningfully different, such
work will be important to help guide selection of patients in
whom dosimetric goals can be met using 3DCRT and those
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in whom the use of IMRT is necessary. As Vicini et al noted,
“We must move away from the notion of IMRT as a modality and focus on what it allows us to do.”23
Our study has numerous strengths, including its inclusion of multiple centers with varying rates of IMRT use, a
diverse patient population and real-world data reported by
both clinicians and patients along with treatment planning
information with greater detail than available through any
other registry of this scale, to our knowledge. However, it
also has limitations. Causal inference from observational
data is notoriously fraught with difﬁculties,29,30 and
although we applied sophisticated analytical techniques to
minimize the effect of treatment selection bias, unmeasured
confounding factors may still have exerted inﬂuence on our
results. However, given the consistent ﬁndings of the one
randomized trial to investigate this important question that
was recently reported from Korea and the low likelihood
that such trials will ever be conducted in the United States,
we believe our ﬁndings represent key real-world evidence to
guide clinical practice and policies in this context in the
United States. Our study represented real-world practice,
but this also resulted in nontrivial amounts of missing data,
which may also introduce biases. Where patient reports of
pain were missing, we relied on physician reports, which are
not as sensitive. In addition, our analyses were based on
patients treated in centers in the state of Michigan. Our
ﬁndings should not be extrapolated to settings where the
quality of radiation therapy care diverges substantially from
that delivered in Michigan or where IMRT approaches differ
substantially or are deﬁned differently from those used by
centers in the current study.
Our study focused exclusively on acute toxicity.
Although late soft tissue effects such as ﬁbrosis in this
setting may well be consequential to severe acute toxicity, they may also develop unexpectedly. Moreover, longterm outcomes, including disease control and late toxicities of other organs that may receive incidental irradiation, are important subjects for future research. It may
be particularly important to use IMRT techniques that
limit the amount of low-dose RT to the lungs and contralateral breast31 because this exposure may have consequences for late toxicity and second malignancy.32 Our
study focused on the use of IMRT to reduce skin toxicity
in node-negative patients; however, inverse-planned
IMRT may also be used to reduce dose to critical normal
structures, including the heart.33-36 On the other hand,
certain IMRT techniques may actually increase dose to
underlying organs, including the heart and lungs, and an
improvement in acute toxicity at the cost of higher doses
to such regions would not be an appropriate trade-off;
further dosimetric analyses are ongoing to evaluate that
concern. With different dose fractionation schemas used,
it is also relevant to investigate toxicity as a function of
the biologically equivalent dose in 2 Gy fractions. Further research is necessary to evaluate the effect of IMRT
in the setting of node-positive disease for the purposes
of cardiac avoidance.4
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Conclusions
What have we learned from this large-scale, prospective
observational analysis of comparative effectiveness of IMRT
versus 3DCRT in the management of breast cancer? First,
there appears to be a modest but signiﬁcant beneﬁt in the
reduction of acute toxicity from the use of more complex
forms of IMRT compared with 3DCRT in the overall patient
population as treated in real-world settings in Michigan,
regardless of whether conventional fractionation or hypofractionation is employed. Second, choice of fractionation
affects acute toxicity far more than choice of technique.
These observations have important implications. Creative
efforts to promote appropriate use of moderate hypofractionation remain most essential,11,37,38 particularly given early
observations of slow uptake of that approach.39,40 Interestingly, IMRT was adopted more quickly—even before evidence of its beneﬁt—than hypofractionation.5 The present
study suggests that uptake of both approaches would minimize rates of acute toxicity, but clinical policy must consider
differences in costs as well. Further research is necessary to
deﬁne dosimetric goals to determine which patients require
IMRT and to optimize patient outcomes and standardize
techniques in this context. Further research is also necessary
to evaluate long-term outcomes and to deﬁne the role of
IMRT in patients being treated with regional nodal
irradiation.41,42
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